Triomics Secures $22 Million Series B Funding Led by Battery Ventures
Triomics has successfully raised $22 million in Series B funding to enhance its AI platform for cancer care across US centers. This investment increases total funding to over $36 million, aiming to improve trial matching and streamline oncology workflows.
Theia Market Signal Identification - AI Assisted
Triomics has raised $22 million in Series B funding led by Battery Ventures, increasing its total funding to over $36 million. The company intends to use the investment to enhance its AI platform, expand its presence in US cancer centers, and strengthen partnerships with life sciences organizations.
The platform has demonstrated significant results, including a 40% increase in trial matches and a 67% reduction in chart review times. Battery Ventures' involvement reflects Triomics' access to major cancer centers and the versatility of its AI infrastructure across multiple oncology processes. This funding could lead to improved operational efficiencies in cancer care, but the challenge remains in managing the vast amount of patient data effectively.
Comments